Navigation Links
Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Date:1/9/2012

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.  IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

IDX184 Phase IIb Study Design
In July 2011, the Company initiated enrollment of treatment-naive genotype 1 HCV-infected patients into a randomized, double-blind, parallel group phase IIb clinical trial of IDX184.  The study features two treatment arms, either 50 mg or 100 mg of IDX184 administered once-daily for 12 weeks, each arm in combination with pegylated interferon and ribavirin (PegIFN/RBV). Study objectives include safety and tolerability, and antiviral activity endpoints.

IDX184 Phase IIb Interim Study Results
The first 31 patients have completed 28 days of treatment, and the interim data have shown that IDX184 was well-tolerated and that there were no serious adverse events associated with therapy. The side effect profile was consistent with that seen with PegIFN/RBV. The independent DSMB has reviewed the data for the first 31 patients and has recommended continuing enrollment of the study. The Company has submitted the interim data, along with the DSMB's recommendations, to the U.S. Food and Drug Administration (FDA) and is requesting the continuation of this study and removal of the partial clinical hold for IDX184.

RVR findings demonstrated that 73% of patients in the 100 mg IDX184 arm (n=15) and 63% in the 50 mg arm (n=16) had undetectable
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Idenix Reports Advancement of HCV Development Pipeline
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
7. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
10. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
(Date:8/20/2014)... NJ (PRWEB) August 20, 2014 WriteResult®, ... announced today that it has expanded its myPROpad™ ePRO ... the EQ-5D-5L, one of the most widely used ... measuring general health status. The EQ-5D is used during ... generate a measure that can be used to demonstrate ...
(Date:8/20/2014)... 2014 GraphDB™ 6.0 ... improvements to the enterprise replication cluster, faster loading ... SOLR and Elasticsearch. This release happens to coincide ... triplestore – GraphDB™ was formerly known as OWLIM. ... only mature enterprise resilient RDF triplestore will also ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Md., April 24 United,Therapeutics Corporation (Nasdaq: ... 2008 first quarter financial results before the open ... Therapeutics will host a half-hour teleconference on Thursday,May ... teleconference is accessible by,dialing 1-800-603-1777, with international callers ...
... an improved governance structure, the benefits of nanotechnology may ... not trust the cutting-edge technology, says David Rejeski, director ... on Thursday, April 24, before the Senate subcommittee on ... dark horse in nanotechnologys future, states Rejeski in his ...
... (Nasdaq: IMRX ) today announced that it ... to which it has satisfied its obligations,under its ... in,connection with its acquisition of urokinase. As a ... remaining inventory of finished,product, all regulatory and clinical ...
Cached Biology Technology:Improved governance needed to realize nanotech's benefits 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3
(Date:8/19/2014)... made to decrease China,s increasing caesarean section rate, suggests ... BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) ... delivery rates in the world. Of 16 million babies ... the exact rate is not known, the current Chinese ... caesarean rates ranging from 36% to 58%. However, before ...
(Date:8/19/2014)... To improve students, chances of completing introductory ... of Houston (UH) implemented a comprehensive student success ... for failure. , Through a grant from ... Department of Biology and Biochemistry embarked on a ... Biology" for non-majors and "Introductory Biology" for science ...
(Date:8/19/2014)... nutrition rating systems be used in supermarkets to encourage ... researchers sought to answer that very question by tracking ... the Guiding Stars System to rate the nutritional value ... Food and Brand Lab,s David Just, PhD, and Brian ... the sales records of over 150 Hannaford Supermarkets in ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... Molecular Biology in July named 12 scientists the winners ... one winner from 2011 will give talks at the ... Stuart Kornfeld, a professor at Washington University in St. ... Chemistry Lectureship. The award recognizes outstanding lifetime scientific ...
... Laboratory,s European Bioinformatics Institute (EMBL-EBI) has been awarded the ... PubMed Central (UKPMC), the free online literature resource for ... has grown from a simple mirror of the National ... a stand-alone site providing access to a repository of ...
... tree trunk, at first sight a colugo might be mistaken ... into a graceful glide, spreading wide the enormous membrane that ... to 150m. So, when Greg Byrnes and his colleague Andrew ... around for a mammal to carry the accelerometer/radio transmitter backpacks ...
Cached Biology News:12 scientists named ASBMB award winners 212 scientists named ASBMB award winners 312 scientists named ASBMB award winners 4European Bioinformatics Institute to lead UK PubMed Central in 2011-2016 2Colugos glide to save time, not energy 2
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: